Type 2 Diabetes Mellitus
Treatment Plan
Investigations
Pathophysiology
Results from a combination of insulin resistance and less severe insulin deficiency
Decreased insulin secretion and increased insulin resistance
- Associated with central obesity, hypertension, hypertriglyceraemia, decreased HDL, modest increase in pro-inflammatory markers
- Insulin binds normally to its receptor on the surface of cells, as normal, thus insulin resistance occurs post receptor
- Most patients show amyloid deposition in Islets in pancreas (co-secreted with insulin)
Diagnostic tests 1
- Random plasma glucose > 11.1mmol/l
- Fasting plasma glucose > 7mmol/l
- For both tests one abnormal value is diagnostic in symptomatic individuals
- Two abnormal values are required in asymptomatic values
Diagnostic tests (for borderline cases)
- Oral glucose tolerance tests (OGTT)
- Fasting >7mmol/l = diabetes diagnosis
- 2hrs after glucose >11.1mmol/l = diabetes diagnosis
Can also detect impaired glucose tolerance (IGT) - a risk factor for future diabetes and cardiovascular disease
- Fasting <7mmol/l
- 2hrs after glucose 7.8 - 11 mmol/l
Haemoglobin A1c
- Measures amount of glycated haemoglobin - thus tells us blood glucose concentrated
- HbA1c> 6.5% normal (48mmol/mol) = diabetes diagnosis
Screen urine for Microalbuminuria
FBC, U&E, liver biochemistry, fasting blood sample for cholesterol and triglycerides
Raised blood pH to look for metabolic acidosis
MDT approach
Educate patient on disease and risks
Encourage regular physical activity and reduction in body weight in the obese
Good glycemic control with good diet -
- Low in sugar
- High in starchy carbohydrates
- High in fibre
- Low in fat
Treatment of hypertension with ACE inhibitors and hyperlipidaemia control
- Orlistat may be given in obesity to reduce the absorption of fat from the diet
- As a second line mechanism, oral metformin may be given
- Reduces rate of gluconeogenesis in the liver
- Increases cells sensitivity to insulin
- Helps with weight issue and reduces CVS risk in diabetes
- Side effects of anorexia, diarrhoea, nausea, abdominal pain, NOT HYPOGLYCAEMIA
- Contraindicated in heart failure, liver disease or renal disease, since can induce lactic acidosis
If HbA1c > 53mmol/l 16 weeks later then add a sulfonylurea (e.g. oral gliclazide)
- Promotes insulin secretion
- These are ineffective in patients without functional cell mass
- Avoided in pregnancy
- Effect wears off as beta-cell mass declines
- Side effects of hypoglycaemia, promote weight gain (avoid in overweight)
- Used in care in those with liver disease and renal impairment
- Safest drug in the elderly
If at 6 months the HbA1c > 57mmol/l consider adding insulin or a glitazone (to replace metformin or sulfonylurea)
Epidemiology
Causes
Signs
Complications
Diabetes is usually primary but may be secondary to other conditions such as:
- Pancreatic pathology
- Endocrine disease e.g. Acromegaly
- Drug induced e.g. corticosteroids
Often overweight around the abdomen
More prevalent in South Asian, African and Caribbean ancestry
Usually older than 30 yrs
Middle Eastern and Hispanic Americans also more at risk
Common in all populations enjoying an affluent lifestyle
Risk factors
Obesity and poor exercise
Ethnicity
Increasing age
Environment
Family history - genetics
Symptoms
Polydipsia
Weight loss
Polyuria and nocturia
Ketosis - but less marked than T1DM
As a presenting feature
Staphylococcal skin infection
Retinopathy found during visit to optician
Polyneuropathy causing tingling and numbness in the feet
Erectile dysfunction
Arterial disease resulting in MI or peripheral gangrene
Breath MAY smell of ketones
Older patients may have retinopathy - DIAGNOSTIC
Evidence of weight loss and dehydration may be present
Acanthosis nigricans - blackish pigmentation at the nape of the neck and in the axillae
Microvascular
Macrovascular
Risk factor for atherosclerosis
Peripheral vascular disease - decreased perfusion due to atherosclerosis
Danger in the retina, glomerulus and nerve sheath
Diabetic retinopathy, nephropathy and neuropathy